Literature DB >> 27269667

General Anesthesia for a Patient With Pelizaeus-Merzbacher Disease.

Nobuhito Kamekura1, Yukie Nitta2, Shigeru Takuma2, Toshiaki Fujisawa3.   

Abstract

We report the successful management of general anesthesia for a patient with Pelizaeus-Merzbacher disease (PMD). PMD is one of a group of progressive, degenerative disorders of the cerebral white matter. The typical clinical manifestations of PMD include psychomotor retardation, nystagmus, abnormal muscle tone, seizures, and cognitive impairment. General anesthesia for a patient with PMD may be difficult mainly because of seizures and airway complications related to poor pharyngeal muscle control. In addition, the possibility of exacerbation of spasticity should be considered. A 20-year-old man with PMD required removal of impacted wisdom teeth under general anesthesia. General anesthesia was induced with thiamylal, fentanyl, and desflurane. Anesthesia was maintained with desflurane and continuous intravenous remifentanil under bispectral index and train-of-4 monitoring. Anesthesia lasted 1 hour 20 minutes and was completed uneventfully. Airway complications, seizures, and exacerbation of spasticity did not occur postoperatively. Preoperatively, our patient had no history of epilepsy attacks or aspiration pneumonia, and no clinical symptoms of gastroesophageal reflux disease. Therefore, exacerbation of spasticity was one of the most likely potential complications. Identification of these associated conditions and evaluation of risk factors during preoperative examination is important for performing safe anesthesia in these patients.

Entities:  

Keywords:  BIS; Body temperature; Desflurane; General anesthesia; Pelizaeus-Merzbacher disease

Mesh:

Substances:

Year:  2016        PMID: 27269667      PMCID: PMC4896048          DOI: 10.2344/15-00022.1

Source DB:  PubMed          Journal:  Anesth Prog        ISSN: 0003-3006


  15 in total

Review 1.  Pelizaeus-Merzbacher disease, Pelizaeus-Merzbacher-like disease 1, and related hypomyelinating disorders.

Authors:  Grace M Hobson; James Y Garbern
Journal:  Semin Neurol       Date:  2012-03-15       Impact factor: 3.420

2.  Muscular hyperactivity after general anaesthesia.

Authors:  M G Soliman; D M Gillies
Journal:  Can Anaesth Soc J       Date:  1972-09

3.  Anaesthetic considerations for the child with leukodystrophy.

Authors:  J D Tobias
Journal:  Can J Anaesth       Date:  1992-04       Impact factor: 5.063

Review 4.  Sevoflurane and epileptiform EEG changes.

Authors:  Isabelle Constant; Robert Seeman; Isabelle Murat
Journal:  Paediatr Anaesth       Date:  2005-04       Impact factor: 2.556

Review 5.  Epilepsy and anesthesia.

Authors:  Marcius Vinícius Mulatinho Maranhão; Eni Araújo Gomes; Priscila Evaristo de Carvalho
Journal:  Rev Bras Anestesiol       Date:  2011 Mar-Apr       Impact factor: 0.964

Review 6.  PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2.

Authors:  Ken Inoue
Journal:  Neurogenetics       Date:  2004-12-31       Impact factor: 2.660

Review 7.  Pelizaeus-Merzbacher disease as a chromosomal disorder.

Authors:  Toshiyuki Yamamoto; Keiko Shimojima
Journal:  Congenit Anom (Kyoto)       Date:  2013-03       Impact factor: 1.409

8.  Effect of general anesthesia in patients with epilepsy: a population-based study.

Authors:  Sarah M Benish; Gregory D Cascino; Mary E Warner; Gregory A Worrell; C Thomas Wass
Journal:  Epilepsy Behav       Date:  2009-11-11       Impact factor: 2.937

Review 9.  Management of status dystonicus: our experience and review of the literature.

Authors:  Paolo Mariotti; Alfonso Fasano; M Fiorella Contarino; Giacomo Della Marca; Marco Piastra; Orazio Genovese; Silvia Pulitanò; Antonio Chiaretti; Anna Rita Bentivoglio
Journal:  Mov Disord       Date:  2007-05-15       Impact factor: 10.338

10.  Epidemiological, clinical, and genetic landscapes of hypomyelinating leukodystrophies.

Authors:  Yurika Numata; Leo Gotoh; Akiko Iwaki; Kenji Kurosawa; Jun-Ichi Takanashi; Kimiko Deguchi; Toshiyuki Yamamoto; Hitoshi Osaka; Ken Inoue
Journal:  J Neurol       Date:  2014-02-16       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.